Abeona Therapeutics Inc. (ABEO) · Aug 13, 2026 · Earnings

The launch is growing—but manufacturing misses are already costing revenue

Miss — Revenue $11.4M vs ~$12.4M consensus; EPS $(0.35) vs $(0.23) consensus

ZEVASKYN revenue rose 31% sequentially, yet missed consensus as two treatments generated no revenue and losses deepened.

The quarter missed the market’s financial bar. Published expectations were roughly $12.4 million of revenue and a $(0.23) per-share loss; Abeona delivered $11.4 million and a $(0.35) loss.

MetricQ2 2026Q1 2026 / consensusRead
ZEVASKYN product revenue$11.4M (Financial Highlights)$8.7M prior quarter (Press release) / ~$12.4M consensus31% sequential growth, but below expectations
Net loss$(20.2)M (Income Statement)$(17.1)M prior quarter (Press release)Loss widened sequentially
Basic and diluted EPS$(0.35) (Income Statement)$(0.30) prior quarter (Press release) / $(0.23) consensusMiss
Cash, equivalents and short-term investments$146.8M (Balance Sheet)$191.4M at December 31, 2025 (Balance Sheet)$44.6M decline year to date

Commercial momentum was real but not enough to offset the miss. Five patients were treated during the quarter and reported revenue increased 31% from Q1, but revenue was recognized for only four treatments because one manufacturing batch failed to produce enough sheets for recognition. Since launch, two additional patients generated no revenue because of low yield or failed lot-release specifications (Commercial update).

Manufacturing reliability is the buried negative. The treatment count suggests demand is developing, but the gap between patients treated and revenue recognized shows that production execution—not just patient onboarding—remains a constraint. That makes the reported $11.4 million less clean than the headline sequential growth implies.

CMS reimbursement creates a genuine offset, but it is future-facing. ZEVASKYN will receive New Technology Add-On Payment status beginning October 1, 2026, which could help hospitals adopt the therapy and improve Medicare access; Medicare patients represent about 10% of the addressable RDEB population (Commercial update). It supports the next leg of launch execution, but does not repair the current-quarter revenue or EPS shortfall.

Net: a launch that is progressing, but below the market’s near-term financial expectation. Lower R&D and SG&A spending helped operating expenses, yet the quarter still produced a larger loss and cash fell to $146.8 million. The filing therefore reads as operationally encouraging in direction, but a clear earnings miss with manufacturing execution still unresolved.

What to watch next

NTAP reimbursement begins October 1, 2026

Original filing on SEC EDGAR

More Abeona Therapeutics Inc. news

The launch is growing—but manufacturing misses are already costing revenue | ABEO Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.